Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib

(2016) Jeffrey C. Bryan et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

HIV-1 Eradication: Early Trials (and Tribulations)

(2016) Adam M. Spivak et al.   TRENDS IN MOLECULAR MEDICINE

Targeting NF-κB Signaling with Protein Kinase C Agonists As an Emerging Strategy for Combating HIV Latency

(2015) Guochun Jiang et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Ex VivoBioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4+T Cells from Aviremic Patients

(2015) Adam M. Spivak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinations

(2015) Gregory M. Laird et al.   JOURNAL OF CLINICAL INVESTIGATION

Global medicinal uses of Euphorbia L. (Euphorbiaceae)

(2015) Madeleine Ernst et al.   JOURNAL OF ETHNOPHARMACOLOGY

An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression

(2015) Gilles Darcis et al.   PLoS Pathogens

Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation

(2015) Guochun Jiang et al.   PLoS Pathogens

Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ–NF-κB signaling

(2014) Guochun Jiang et al.   AIDS

Ruxolitinib and Tofacitinib Are Potent and Selective Inhibitors of HIV-1 Replication and Virus ReactivationIn Vitro

(2014) Christina Gavegnano et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat

(2014) N. M. Archin et al.   JOURNAL OF INFECTIOUS DISEASES

New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo

(2014) C Korin Bullen et al.   NATURE MEDICINE

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

(2014) Eun Bong Lee et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dual Role of Novel Ingenol Derivatives from Euphorbia tirucalli in HIV Replication: Inhibition of De Novo Infection and Activation of Viral LTR

(2014) Celina M. Abreu et al.   PLoS One

Reactivation of latent HIV-1 by new semi-synthetic ingenol esters

(2014) Diego Pandeló José et al.   VIROLOGY

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

(2014) Thomas A Rasmussen et al.   Lancet HIV

A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral Therapy

(2013) A. M. Spivak et al.   CLINICAL INFECTIOUS DISEASES

An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients

(2013) Celsa A. Spina et al.   PLoS Pathogens

Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study

(2012) JP Routy et al.   HIV MEDICINE

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

(2012) N. M. Archin et al.   NATURE

Shock and kill

(2012) Steven G. Deeks   NATURE

Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication

(2010) Tae-Wook Chun et al.   AIDS

Bryostatin-1 Synergizes with Histone Deacetylase Inhibitors to Reactivate HIV-1 from Latency

(2010) Moises Perez et al.   CURRENT HIV RESEARCH

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE